Patents by Inventor Louis Fabri
Louis Fabri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220089778Abstract: A membrane targeted binding protein that binds to at least one blood coagulation factor, wherein the binding protein has pro-coagulant activity.Type: ApplicationFiled: October 8, 2021Publication date: March 24, 2022Inventors: Peter SCHMIDT, Chao-Guang CHEN, Con PANOUSIS, Louis FABRI
-
Publication number: 20190248920Abstract: A membrane targeted binding protein that binds to at least one blood coagulation factor, wherein the binding protein has pro-coagulant activity.Type: ApplicationFiled: September 22, 2017Publication date: August 15, 2019Inventors: Peter SCHMIDT, Chao-Guang CHEN, Con PANOUSIS, Louis FABRI
-
Publication number: 20080057517Abstract: The present invention relates generally to a method for regulating cytokine signalling and agents useful for same. The method of the present invention is predicated in part on the identification of the molecular target of suppressor of cytokine signalling (SOCS) interaction in controlling cytokine signalling. The identification of the molecular target permits the development of assays to screen for a range of agonists and antagonists useful in modulating cytokine function. The present invention further provides, therefore, screening assays and more particularly high through-put screening assays for agonists and antagonists of SOCS-receptor interaction. Such agonists and antagonists are useful in the manufacture of medicaments for controlling cytokine signalling. Control of cytokine signalling is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders and any other conditions involving aberrations of signal transduction.Type: ApplicationFiled: June 15, 2007Publication date: March 6, 2008Applicant: The Walter and Eliza Institute of Medical ResearchInventors: Sandra Nicholson, Manuel Baca, Nicos Nicola, Douglas Hilton, Jian Zhang, Louis Fabri, Andrew Nash
-
Publication number: 20080009444Abstract: The present invention relates generally to a biologically active complex comprising at least two heterologous molecules. More particularly, the biologically active complex of the present invention comprises at least two polypeptides or parts, fragments, truncates or protease-activated forms of one or more of the polypeptides wherein the complex alone or in association with a receptor, ligand or other molecule facilitates proliferation, differentiation and/or survival of a cell. The identification of the biologically active complex of the present invention permits the assay for agonists and antagonists of the formation of the biologically active complex as well as therapeutic and diagnostic reagents based on the biologically active complex or interaction between the biologically active complex and a receptor, ligand or other molecule.Type: ApplicationFiled: February 8, 2007Publication date: January 10, 2008Applicant: Zenyth Operations Pty LtdInventors: Andrew Nash, Kim Jachno, Louis Fabri, Kate Reid, Perry Bartlett, Douglas Hilton, Yasuhiko Nakata, Masakazu Hasegawa
-
Patent number: 7256007Abstract: The present invention relates generally to a method for regulating cytokine signaling and agents useful for same. The method of the present invention is predicated in part on the identification of the molecular target of suppressor of cytokine signaling (SOCS) interaction in controlling cytokine signaling. The identification of the molecular target permits the development of assays to screen for a range of agonists and antagonists useful in modulating cytokine function. The present invention further provides, therefore, screening assays and more particularly high through-put screening assays for agonists and antagonists of SOCS-receptor interaction. Such agonists and antagonists are useful in the manufacture of medicaments for controlling cytokine signaling. Control of cytokine signaling is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders and any other conditions involving aberrations of signal transduction.Type: GrantFiled: March 9, 2001Date of Patent: August 14, 2007Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Sandra Elaine Nicholson, Manuel Baca, Nicos A. Nicola, Douglas Hilton, Jian Guo Zhang, Louis Fabri, Andrew Nash
-
Patent number: 7220828Abstract: The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: GrantFiled: March 10, 1998Date of Patent: May 22, 2007Assignee: Zenyth Operations Pty LtdInventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Jian-Guo Zhang, Alison Farley, Warren Alexander, Steven Rakar, Yasufumi Kikuchi, Tetsuo Kojima, Masatsugu Maeda, Louis Fabri, Andrew Nash
-
Publication number: 20070111944Abstract: The present invention provides a method for purifying recombinant peptides, polypeptides or proteins away from truncated or other full-length forms of these molecules. In particular the invention contemplates a method of purifying a vascular endothelial growth factor (VEGF) molecule by subjecting a biological sample containing the molecule to be purified to affinity chromatography under conditions sufficient for the full length molecules to bind and not the truncated or clipped forms. In the preferred embodiment there are two columns, the first is based on affinity for a poly his tag, the second column based on heparin binding affinity. Particularly preferred VEGF molecules are untagged VEGF-B167, hexa-His-tagged VEGF-B167, hexa-His-tagged VEGF-B186 and hexa-His-tagged VEGF-B10-108.Type: ApplicationFiled: October 2, 2006Publication date: May 17, 2007Inventors: Sergio Scrofani, Andrew Nash, Louis Fabri, Andrew Mackenzie, Pierre Scotney
-
Publication number: 20060294608Abstract: The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: August 24, 2006Publication date: December 28, 2006Applicant: Zenyth Operations Pty LtdInventors: Douglas Hilton, Nicos Nicola, Alison Farley, Tracy Willson, Jian-Guo Zhang, Warren Alexander, Steven Rakar, Louis Fabri, Tetsuo Kojima, Masatsugu Maeda, Yasufumi Kikuchi, Andrew Nash
-
Publication number: 20050058645Abstract: The present invention relates generally to antibodies that bind to the Interleukin-13 receptor ?1 chain (IL-13R?1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R?1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R?1/ligand interaction is also provided.Type: ApplicationFiled: May 20, 2004Publication date: March 17, 2005Applicant: AMRAD OPERATIONS PTY. LTD.Inventors: Felicity Dunlop, Manuel Baca, Andrew Nash, Louis Fabri, Douglas Hilton, Nicos Nicola
-
Publication number: 20030191058Abstract: The present invention relates generally to a method for regulating cytokine signalling and agents useful for same. The method of the present invention is predicated in part on the identification of the molecular target of suppressor of cytokine signalling (SOCS) interaction in controlling cytokine signalling. The identification of the molecular target permits the development of assays to screen for a range of agonists and antagonists useful in modulating cytokine function. The present invention further provides, therefore, screening assays and more particularly high through-put screening assays for agonists and antagonists of SOCS-receptor interaction. Such agonists and antagonists are useful in the manufacture of medicaments for controlling cytokine signalling. Control of cytokine signalling is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders and any other conditions involving aberrations of signal transduction.Type: ApplicationFiled: February 19, 2003Publication date: October 9, 2003Inventors: Sandra Elaine Nicholson, Manuel Baca, Nicos A Nicola, Douglas Hilton, Jian Guo Zhang, Louis Fabri, Andrew Nash